A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Recruiting
Loxo Oncology, Inc.
Phase 1/Phase 2
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL
and NHL who have failed or are intolerant to standard of care.
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Recruiting
Loxo Oncology, Inc.
Phase 3
This is a study for participants with a type of blood cancer called mantle cell lymphoma
(MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that
have already been approved by the United States Food and Drug Administration (US FDA).
Participation could last up to two years, and possibly longer, if the disease does not
progress.
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL
Recruiting
Loxo Oncology, Inc.
Phase 3
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main
purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab.
Participation could last up to four years, and possibly longer, if the disease does not
progress.
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Recruiting
Eli Lilly and Company
Phase 2
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with
lymphoma or chronic leukemia who have already had standard of care treatment. Participation
could last up to four years.
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Recruiting
Loxo Oncology, Inc.
Phase 3
The purpose of this study is to compare the efficacy and safety of fixed duration
pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with
CLL/SLL who have been previously treated with at least one prior line of therapy.
Participation could last up to five years.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
